Bellicum Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Bellicum Pharmaceuticals has been growing earnings at an average annual rate of 44.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 0.8% per year.
Key information
44.5%
Earnings growth rate
64.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -0.8% |
| Return on equity | -486.1% |
| Net Margin | -1,484.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Bellicum Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 2 | -22 | 7 | 0 |
| 30 Jun 23 | 2 | -29 | 7 | 0 |
| 31 Mar 23 | 2 | -25 | 6 | 0 |
| 31 Dec 22 | 2 | -25 | 6 | 0 |
| 30 Sep 22 | 2 | -16 | 6 | 0 |
| 30 Jun 22 | 6 | -8 | 6 | 0 |
| 31 Mar 22 | 6 | -6 | 6 | 0 |
| 31 Dec 21 | 6 | -10 | 7 | 0 |
| 30 Sep 21 | 6 | 7 | 9 | 0 |
| 30 Jun 21 | 1 | 4 | 11 | 0 |
| 31 Mar 21 | 1 | -37 | 13 | 0 |
| 31 Dec 20 | 1 | -8 | 16 | 0 |
| 30 Sep 20 | 5 | -55 | 18 | 0 |
| 30 Jun 20 | 5 | -87 | 23 | 0 |
| 31 Mar 20 | 7 | -70 | 27 | 0 |
| 31 Dec 19 | 7 | -112 | 30 | 0 |
| 30 Sep 19 | 2 | -111 | 31 | 0 |
| 30 Jun 19 | 3 | -102 | 29 | 0 |
| 31 Mar 19 | 1 | -100 | 27 | 0 |
| 31 Dec 18 | 1 | -98 | 25 | 0 |
| 30 Sep 18 | 1 | -93 | 23 | 0 |
| 30 Jun 18 | 1 | -92 | 21 | 0 |
| 31 Mar 18 | 0 | -93 | 21 | 0 |
| 31 Dec 17 | 0 | -92 | 21 | 0 |
| 30 Sep 17 | 0 | -90 | 20 | 0 |
| 30 Jun 17 | 0 | -84 | 20 | 0 |
| 31 Mar 17 | 0 | -76 | 19 | 0 |
| 31 Dec 16 | 0 | -69 | 17 | 0 |
| 30 Sep 16 | 0 | -66 | 17 | 0 |
| 30 Jun 16 | 0 | -62 | 16 | 0 |
| 31 Mar 16 | 0 | -56 | 15 | 0 |
| 31 Dec 15 | 0 | -49 | 13 | 0 |
| 30 Sep 15 | 0 | -106 | 11 | 0 |
| 30 Jun 15 | 1 | -97 | 8 | 0 |
| 31 Mar 15 | 1 | -90 | 6 | 0 |
| 31 Dec 14 | 2 | -85 | 4 | 0 |
| 30 Sep 14 | 3 | -14 | 3 | 0 |
| 30 Jun 14 | 3 | -12 | 3 | 0 |
| 31 Mar 14 | 2 | -10 | 3 | 0 |
| 31 Dec 13 | 2 | -9 | 2 | 0 |
Quality Earnings: BPXA is currently unprofitable.
Growing Profit Margin: BPXA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPXA is unprofitable, but has reduced losses over the past 5 years at a rate of 44.5% per year.
Accelerating Growth: Unable to compare BPXA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPXA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: BPXA has a negative Return on Equity (-486.06%), as it is currently unprofitable.